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Introduction
Matrix metalloproteinases (MMPs) are the family of
structurally related zinc dependent endopeptidases
[1]. They are classified into subgroups of collage-
nases, stromelysins and gelatinases. Metallopro-
teinase-9 (MMP-9) is one of gelatinases, which is
capable of degrading type IV collagen, main compo-
nent of basement membrane. MMP-9 plays impor-
tant role in the invasiveness [1] and metastatic
potential of tumor cells through increased vessel per-
meation [2]. 
Esophageal cancer (EC) is one of the most aggres-
sive malignant tumors and relatively common [3],
especially in developing countries [4]. The mortality
rates of this tumor are similar to the incidence rates,
because of rapid progression, late stage of diagnosis,
and poor prognosis [5]. Several studies showed high
MMP-9 protein expression in tumor tissues of
esophageal cancer patients [6-8]. Moreover, high
MMP-9 expression in esophageal cancer correlated
significantly with the depth of tumor invasion, lym-
phatic vessel permeation, nodal metastases and differ-
entiation grade [2,9]. In addition, in multivariate
analysis, high expression of MMP-9 in esophageal
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cancer tissue was a negative prognostic factor [9]. The
recent study has shown that the preoperative serum
levels of MMP-9 in esophageal cancer patients were
statistically higher than in healthy subjects and corre-
lated with clinical stage of disease as well as with
tumor size [10]. The diagnostic sensitivity of serum
MMP-9 measurement was higher than for classical
tumor markers (carcinoembryonic antigen, CEA and
squamous cell cancer antigen, SCC-Ag) and increased
in the combination of MMP-9 with SCC-Ag [10].
Moreover, the presence of MMP-9 in esophageal can-
cer cells was proved by the immunohistochemical
staining [10]. 
The aim of the current study was to compare the
association between the intensity of MMP-9 expression
in neoplastic cells and in the interstitial inflammatory
infiltrate in esophageal cancer with clinicopathological
features of esophageal cancer. Additionally, we evaluat-
ed the expression of MMP-9 in different histopatologi-
cal types of esophageal cancer, e.g. adenocarcinoma and
esophageal squamous cell carcinoma. 
Materials and methods
Patients. Thirty-two patients with esophageal cancer were
enrolled in this study (28 males and 4 females, aged 49-77
years). The samples for immunohistochemical staining were col-
lected during surgery. All tumors were verified histopathologi-
cally (17 cases of squamous cell carcinoma and 15 cases of ade-
nocarcinoma). Clinical status of patients was classified accord-
ing to the pathological tumor, node, metastasis (pTNM) classifi-
cation system [11]. TNM staging of the tumor showed 11
patients in stage I+II (early stage) and 21 patients in stage III+IV
(advanced). The patients were grouped based on the tumor size,
depth of tumor invasion (T factor) and lymph node metastases
(N factor) (Table 1). 
Immunohistochemical (IHC) staining. The tissue samples were
fixed in 10% buffered formalin, dehydrated and embedded in
paraffin. Mice monoclonal antibodies against human matrix metal-
loproteinase-9 (Novocastra; clone15W2; dilution 1:40) were used
for detection of metalloproteinase-9 expression. RE7110-K Novo-
castra Peroxidase Detection System was used for the visualization
of the antigen presence. The antigen retrieval was preformed by
microvawe boiling of the paraffin sections 4 µm thick Tissue sam-
ples were elaborated according to the protocol recommended by
manufacturer of assay kits (Novocastra). All the procedures were
accompanied by positive (human liver) and negative (without pri-
mary antibody) controls. The light microscopy was used to evalu-
ate the expression of metalloproteinase-9 in neoplastic tissue using
semi-quantitative scale: 0 pt – no reaction; 1 pt – weak reaction; 2
pts – moderate reaction; 3 pts – intense reaction. Intensity of the
metalloproteinase positive inflammatory infiltrate (macrophages,
polinuclears and lymphocytes) in the neoplastic interstitium was
evaluated in the same scale. 
Statistical analysis. It was revealed in Chi-square test as prelimi-
nary statistical analysis that the intensity of MMP-9 expression
did not follow a normal distribution. Therefore the nonparamet-
ric Mann – Whitney U-test was used. Data are presented as per-
cent and mean value of MMP-9 expression in each analyzed sub-
group. Statistically significant differences were defined as com-
parison resulting in p<0.05. Statistical analyses were performed
using the STATISTICA 5.1 PL software (StatSoft Inc., Tulsa,
OK, USA). 
Results
The expression of matrix metalloproteinase-9 in
esophageal cancer cells
The expression of MMP-9 (Fig. 1) was evaluated
using semi-quantitive scale. Intensity of expression
was individually different, from null (0 pt) to intense
reaction (3 pts). A positive reaction (Table 2) was
observed in 81% of all esophageal cancer tissue sam-
ples, in which weak (1 pt) in 53%, moderate (2 pts)
in 16% and an intense expression (3 pts) in 12% of
cases. 
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Table 1. Characteristics of esophageal cancer patients.
Fig. 1. The expression of matrix metalloproteinase-9 in esophageal
cancer cells.
The relationship between the intensity of MMP-9
expression in neoplastic tissue and clinicopathologi-
cal features of esophageal cancer were compared
(Table 2). The percentage of positive MMP-9 expres-
sion was higher in advanced stage of tumor (III+IV)
when compared to early stage of EC (I+II).
Immunostaining revealed a positive reaction in 25%
of cases in early stage of disease whereas 56% of
those from patients being in advanced stage. There
were more of weak, moderate and intense reactions in
subgroup III+IV (34%, 13% and 9%, respectively)
than in tumor samples from patients with early stage
(19%, 3% and 3%, respectively). 
Similar results were observed when analyzed rela-
tionships between MMP-9 expression with tumor size
(diameter). In patients with tumors of 4 cm or greater
the immunostaining revealed that the expression of
MMP-9 was higher (53%) than in subgroup with tumors
smaller than 4 cm (28%). Additionally, the number of
weak (1 pt) and intense reactions (3 pts) in tumors above
4 cm (38% and 9%, respectively) was higher than in
smaller tumors (16% and 3%, respectively). 
It was shown that expression of MMP-9 in cancer
cells was dependent on the depth of tumor invasion (T
factor). There were eight times more cases with posi-
tive reactions (72%) in the T3+T4 subgroup of EC
samples than in the T1+T2 patients (9%). Moreover,
there were more of weak, moderate and intense reac-
tions in subgroup T3+T4 (47%, 13% and 13%, respec-
tively) than in tumor samples from subroup T1+T2
(6%, 3% and 0%, respectively). 
The MMP-9 expression in tumor samples from
patients with lymph node metastases (N1) was higher
than in samples from N0 subgroup. There were more
positive reactions in N1 group (56%) than in patients
without nodal metastases (N0 group – 25%). The results
have also shown the higher number of moderate (34%),
intense (13%) and positive reactions (9%) in patients
with lymph node metastasis (N1) in comparison to the
N0 subgroup (19%, 3% and 3%, respectively). 
Additionally, the intensity of immunostainig in dif-
ferent histopatological types of cancer was analyzed.
The percentage of MMP-9-positive reactions in the
subgroup of squamous cell carcinoma (47%) was
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Table 2. The expression of matrix metalloproteinase-9 in esophageal cancer cells in relation to clinicopathological features of tumor.
found to be higher than in adenocarcinoma subgroup
(34%). 
The expression of matrix metalloproteinase-9 in
inflammatory infiltrate cells
Table 3 shows the expression of MMP-9 in interstitial
inflammatory infiltrate in esophageal cancer cells in
relation to clinicopathological features of tumor. Posi-
tive reaction was observed in 75% of cases, where
weak expression of MMP-9 was identified in 34%,
moderate in 19% and intensive in 22% of tumor sam-
ples. Additionally, we analyzed the relationship
between MMP-9 expression in inflammatory cells
(macrophages, polinuclears and lymphocytes) and
clinicopathological parameters of tumor. There were
more positive cases in advanced stage (44%) in com-
parison to subgroup of early cancer (31%). However,
we have observed higher number of positive cases
with weak (1 pt) and intense (3 pts) expression of
MMP-9 in advanced stage subgroup. 
In the analysis of relationship between MMP-9
expression in inflammatory infiltrate with tumor size
the same number of positive cases in both subgroups
(38%) was observed, although the percentage of
intense expression was higher in samples from patients
with tumor size above 4 cm (16%) than in subgroup
with smaller tumors (6%) (Table 3). 
We have observed more cases of positive MMP-9
staining in T3+T4 subgroup (63%) than in T1+T2
(12%). Similarly, the percentage of weak, moderate
and high intensity of expression was identified in T3+4
group (25%, 16% and 22%, respectively) in compari-
son with T1+T2 subgroup (9%, 3% and 0%, respec-
tively). 
Moreover, the number of positive reactions (47%)
in patients with lymph node metastases (N1 subgroup)
was found to be higher when compared with patients
in N0 subgroup (28%). The percentage of weak (1 pt)
and intense reactions (3 pts) were higher in N1 patients
(25% and 16%, respectively) versus subgroup N0 (9%
and 6%, respectively). 
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Table 3. The expression of matrix metalloproteinase-9 in interstitial inflammatory infiltrate cells of esophageal cancer in relation to clin-
icopathological features of tumor.
Additionally, we analyzed immunostainig in differ-
ent histopatological types of cancer. We observed
almost two-fold higher percentage of positive MMP-9
reactions in inflammatory cells in the subgroup of
squamous cell carcinoma (47%) than in adenocarcino-
ma subgroup (28%). In the subgroup of squamous cell
carcinoma weak (1 pt) and moderate expression (2 pts)
of MMP-9 was higher (25% and 13%, respectively)
than in the adenocarcinoma subgroup (9% and 6%,
respectively). 
Mean values of MMP-9 expression
Table 4 shows mean values of MMP-9 in esophageal
cancer tissue and in inflammatory cells, which were
evaluated using semi-quantitative scale. The mean
value of MMP-9 expression was higher in inflam-
matory infiltrate (1.37) than in cancer cells (1.21),
although this difference was not statistically signif-
icant. We have assessed the relationship between
mean MMP-9 expression and clinicopathological
characteristic of tumors. The mean expression of
this enzyme in cancer cells was higher in advanced
stage (III+IV subgroup) of esophageal cancer (1.33)
than in early stage of tumor (1.33), but in inflam-
matory cells lower in III+IV subgroup (1.64) than in
I+II (1.24). Similar results were observed in relation
to tumor size and node lymph metastases. The mean
value for tumors above 4 cm and in N1 subgroup
was higher in cancer cells and lower in inflammato-
ry infiltrate than these values for smaller tumors as
well as in N0 tumors. The mean expression of
MMP-9 in T3+T4 group was higher than in T1+T2
tumors as well in cancer as in inflammatory infil-
trate cells. All these differences were not statistical-
ly significant.
Additionally, we analyzed values of MMP-9
expression in different histopatological types of
esophageal cancer. The mean values in squamous car-
cinoma were higer in esophageal cancer (1.29) and
inflammatory cells (1.47) in comparison to adenocar-
cinoma (1.13 and 1.27, respectively), but these differ-
ences were not statistically significant.
Discussion
Esophageal cancer is one of the most aggressive
malignant tumors. Despite recent advances in diagno-
sis and treatment of this malignancy, the prognosis for
EC patients is still poor in comparison with other
tumors of digestive tract. Degradation of extracellular
matrix (ECM) is thought to be one of key steps of
invasion and metastasis of esophageal cancer. Matrix
metalloproteinases are able to degrade ECM and facil-
itate progression of neoplastic tumors. 
High MMP-9 protein expression in tumor tissues
from EC patients was shown in several studies [6-8]
while normal esophagus epithelium expressed no
detecTable tissue level of this enzyme [7,8]. The
expression of MMP-9 correlated with clinicopatholog-
ical factors, such as depth of tumor invasion (T), lym-
phatic vessel permeation, nodal metastasis (N) and
pathological differentiation of tumor (G) [2,9]. The
most common technique to investigate MMPs protein
expression is the evaluation in immunohistochemical
staining, a semiquantitive and subjective method,
employing tissue samples preparation. In this study we
assessed the expression of MMPs in tumor tissue sam-
ples – as well in esophageal cancer cells as in the
inflammatory infiltrate cells in surrounding tissue.
In our study we proved the presence of MMP-9 in
the tumor by immunostaining. The deposits of MMP-
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Table 4. Mean values of MMP-9 expression in esophageal cancer and inflammatory cells.
9 were localized as well in the cytoplasm of neoplas-
tic cells as well in inflammatory cells, e.g.
macrophages, polinuclears and lymphocytes. The
intensity of the enzyme expression in cancer cells
was assessed, using semi-quantitative scale: 0 pt – no
reaction, 1 pt – weak, 2 pts – moderate and 3 pts –
intense reaction. Mean values of MMP-9 expression
intensity was determined for each analyzed subgroup
of patients. 
The positive reaction in cancer cells was observed
in 81% of specimens. Moreover, there was a tendency
to increase the intensity of immunostaining in more
advanced stages of tumor – 25% MMP-9 positive
cases in early and 56% in advanced stage of EC,
although we have not found statistically significant
differences between mean tissue expression and TNM
stage. We found that mean value of expression of
MMP-9 in EC was higher in more advanced stage of
disease (I+II versus III+IV) and increased with tumor
size, depth of tumor invasion and presence of metas-
tases in lymph nodes, what may probably be the result
of enhanced production of this enzyme by cancer cells.
The findings are in agreement with those obtained by
El-Shahat et al. [7]. They showed a positive expression
of MMP-9 in 36% of cases in stage I, 75% in stage II,
90% in stage III and 100% in stage IV of EC patients.
Therefore, higher expression of MMP-9 in patients
with more advanced esophageal cancer might be a
result of the enzyme production by cancer cells [7]. 
Moreover, we observed higher percentage and
mean values of MMP-9 expression in the subgroup of
squamous cell carcinomas in comparison to the ade-
nocarcinomas subgroup, although the two main types
of EC invade and spread in a similar manner and have
an equally poor prognosis [6]. The different expres-
sion of MMP in both histopatlogical types of EC may
be the result of marked differences in the pathogene-
sis, tumor location, tumor biology of adenocarcinoma
of esophagus and squamous cell carcinoma [12].
Additionally, the current study assessed the metal-
loproteinase expression in inflammatory cells. Infil-
tration of inflammatory cells is a prominent and char-
acteristic feature of many malignant tumors. The
inflammatory cells produce metalloproteinases to the
peritumoral environment. These cells are also able to
synthesize various cytokines enhancing expression of
MMPs by both tumoral and stromal cells [13]. Inten-
sity of the metalloproteinase positive inflammatory
infiltrate (macrophages, polinuclears and lympho-
cytes) in the neoplastic interstitium was evaluated in
the same score as in cancer cells. The positive reac-
tion in inflammatory infiltrate cells was observed in
75% of specimens. There was also a tendency to
increase the intensity of MMP-9 expression in
advanced stages of tumor – 44% of MMP-9 positive
cases in comparison to early stages – 31 %.
The mean expression of MMP-9 was higher in
inflammatory infiltrate than in cancer cells. Interest-
ingly, the mean value of MMP-9 expression in
inflammatory infiltrate cells was higher in early
stages of EC than those in advanced stages, whereas
the percentage of positive reactions and mean expres-
sion of this enzyme in cancer cells increased with
tumor stage. This more intense reaction in less
advanced stage of disease may be the result of syn-
thesis of MMP 9 rather by inflammatory cells, e.g.
tumor associated macrophages, polynuclear granulo-
cytes and lymphocytes than by cancer cells [14]. In
cancer tissue, infiltration of inflammatory cells has
been suggested to be a mechanism of host resistance
[15]. 
This is the first study comparing the expression of
metalloproteinase-9 in cancer and inflamatory infil-
trate cells in different types of esophageal cancer, e.g.
squamous cell cancer and adenocarcinoma of esoph-
agus. We proved the synthesis of MMP-9 by cancer
cells as well as by inflammatory cells and its correla-
tion with tumor stage, tumor size, depth of tumor
invasion and lymph node metastases. In conclusion,
high incidence of MMP-9 expression in esophageal
cancer tissue samples and its increased intensity in
higher stages of EC suggest the important role of
matrix metalloproteinase-9 in esophageal tumorigen-
esis, although this issue requires additional studies.
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